Maker of the Organ Care System, a portable device that keeps donor organs warm and functioning during transport for transplant.
Maker of the Organ Care System, a portable device that keeps donor organs warm and functioning during transport for transplant.
Earns per transplant: a hospital pays for the single-use organ kit and for a bundled service in which TransMedics' own surgeons, pilots and aircraft retrieve the organ and fly it back. That service side has grown into a large part of what it bills, which is why it has bought its own planes.
Moat: narrow (IP / patents, regulatory licence, installed base). Patented warm-perfusion technology plus its own logistics network expand usable donor organs, hard to replicate quickly.
Headquarters: Andover, Massachusetts · Founded: 1998 · Employees: 898
Size TransMedics (TMDX) is a United States Health Care company (Medical Specialties) with a market value of $3.35B, the 1467th largest of 3,085 United States companies the cockpit tracks. Shares closed at $96.43 on 18 Nov 2026.
Performance Over six months the shares gained 41.8%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 28.5% over the last twelve months (peer median +5.7%); the operating margin is 12.0% (peer median 7.3%).
Valuation It trades at 43.4× forward earnings against a peer median of 25.1× (5th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +88%, so the hurdle is -50 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.2 points below its cost of capital (13.6% WACC).
Credit TransMedics has 1 bond outstanding ($460M).
Short interest Short interest is 25.6% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $728M | $605M | $442M | $242M | $93.5M |
| Revenue growth | — | +37% | +83% | +159% | — |
| Gross profit | $416M | $363M | $262M | $154M | $65.3M |
| EBITDA | $128M | $136M | $57.3M | $8.76M | -$27.2M |
| Net income | $144M | $190M | $35.5M | -$25.0M | -$36.2M |
| Free cash flow | $44.7M | $134M | -$80.9M | -$165M | -$57.7M |
| Capital expenditure | $67.7M | $59.3M | $130M | $179M | $11.9M |
| Total debt | $867M | $519M | $518M | $516M | $67.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| TransMedics TMDX | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% |
| Xvivo Perfusion XVIVO.ST | $611M | -32% | +18% | 12% | 53.1× | 35.9% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TMDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.0% | -0.2% | 2nd highest of 21 |
| 6-month return | +41.8% | +3.2% | 5th highest of 21 |
| Distance from 52-week high | -38.2% | -22.1% | 6th lowest of 21 |
| Revenue growth (TTM) | +28.5% | +5.7% | 4th highest of 21 |
| Operating margin | 12.0% | 7.3% | 8th highest of 20 |
| Forward P/E | 43.4× | 25.1× | 5th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 38.4% | 11.3% | 6th most demanding of 17 |
| Growth delivered (Del g) | +88.2% | +8.5% | highest of 17 |
| Hurdle (Req g minus delivered) | -49.8 pp | +1.7 pp | least demanding of 17 |
| ROIC minus cost of capital | -6.2 pp | -1.1 pp | 4th lowest of 19 |
| EV / EBITDA | 29.2× | 16.3× | 5th most expensive of 11 |
| Net debt / EBITDA | 2.9× | 0.1× | most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
TransMedics has 1 bond outstanding with $460M face value.